Write in a clean editor, then format for EJC Paediatric Oncology in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
EJC Paediatric Oncology is a peer-reviewed journal published by Elsevier, covering Childhood Cancer Survivors' Quality of Life, Neuroblastoma Research and Treatments, Acute Lymphoblastic Leukemia research.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, EJC Paediatric Oncology 12 (2023) 45–58.
Formats any DOI in EJC Paediatric Oncology style. No sign-up. |
| Publishes research in | Childhood Cancer Survivors' Quality of Life Neuroblastoma Research and Treatments Acute Lymphoblastic Leukemia research Acute Myeloid Leukemia Research Glioma Diagnosis and Treatment |
| ISSN | 2772-610X |
| Citation impact (2-yr) | 1.05 |
| h-index | 11 |
| i10-index | 12 |
| Total citations | 709 |
| Open access | Yes |
| Top institutions publishing here | Princess Máxima Center |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Osteosarcoma is a challenging disease requiring multidisciplinary management in expert centers for optimal outcome. There are no current international protocols or guidelines specific for pediatric and adolescent osteosarcoma. The European Standard Clinical Practice (ESCP) project is a collaboration between ERN PaedCan and SIOP Europe's Clinical Trial Groups to develop approved clinical recommendations reflecting current best…
The treatment of medulloblastoma has evolved considerably over the last 10 years. Treatment intensity is now stratified within clinical trials, using risk-associated clinical features and molecular biomarkers, aimed at maximising cure rates whilst minimising long-term disease and therapy-associated side-effects. In Europe, we have developed a long-term strategy of using randomised trials to test stratified treatments…
Despite intensive therapies, pediatric patients with relapsed or refractory solid tumors have poor outcomes and need novel treatments. Immune therapies offer an alternative to conventional treatment options but require the identification of differentially expressed antigens to direct antitumor activity to sites of disease. B7-H3 (CD276) is an immune regulatory protein that is expressed in a…
Neuroblastoma is a cancer of the sympathetic nervous system that develops in young children, either as low-risk or high-risk disease. The tumor microenvironment (TME) is now recognized as an important player of the tumor ecosystem that may promote drug resistance and immune escape. Targeting the TME in combination with therapies directly targeting tumor cells therefore…
BackgroundThe role of vincristine as a contributing risk factor for hearing loss among childhood cancer survivors (CCS) treated with platinum-based chemotherapy has not been fully elucidated. We examined the association of vincristine with hearing loss in a national cohort of CCS.MethodsWe included CCS registered in the Swiss Childhood Cancer Registry diagnosed at age ≤ 18…
